cute heart failure syndrome (AHFS) is a clinical syndrome associated with a variety of underlying diseases, and remains a major clinical challenge, with a high and increasing incidence and substantial morbidity and mortality. 1 Large, controlled trials of chronic heart failure (HF) have identified treatments that improve clinical outcomes, whereas the management and outcome of AHFS have not changed over the past 2 decades. The Guidelines of the European Society of Cardiology and American Heart Association and the practical recommendation of a consensus workshop for the treatment of AHFS are that pharmacotherapy with vasodilators is preferable to inotropic agents in patients without excessively low blood pressure (BP). [2] [3] [4] Nicorandil has nitrate-like properties and activates the ATPsensitive potassium (KATP) channels, resulting in balanced venous and arterial vasodilation. 5 Intravenous administration of nicorandil by bolus injection followed by continuous infusion improves the pulmonary capillary wedge pressure and cardiac index in patients with AHFS immediately and continuously as a potent vasodilator with combined preload and afterload reduction. 6, 7 Nicorandil also exhibits cardioprotective effects in the ischemic myocardium, similar to those of ischemic preconditioning, via activation of mitochondrial KATP channels. 8 Several studies have demonstrated that nicorandil can reduce infarct size and improve functional and clinical outcomes after acute myocardial infarction when administered adjunctively with coronary intervention. 9-11 However, there are no reports of the effects on clinical outcome of nicorandil treatment in the urgent phase of AHFS. This study was conducted to evaluate the effect of intravenous nicorandil on the mid-term prognosis of patients with AHFS.
Methods

Data Sources
This was a single center, retrospective and observational study. A total of 428 consecutive patients who were hospitalized for AHFS (including acute exacerbation of chronic HF) for the first time between January 2005 and December 2009 were evaluated; 28 patients were excluded because they had acute coro-ISHIHARA S et al.
nary syndrome (n=26) or right HF (n=2). Thus, 402 patients were finally included in this study.
Patients and Nicorandil Administration
After hospital admission, nicorandil was administered at the discretion of the physician caring for the patient. A total of 402 patients were divided into a Nicorandil group (n=78; 19.4%) who received intravenous administration of nicorandil and a Control group (n=324) who did not receive nicorandil during hospitalization. Intravenous administration of nicorandil was started in the emergency department within 1 h of hospitalization with a bolus injection of 0.1-0.2 mg/kg, followed by continuous infusion of 0.1 mg · kg -1 · h -1 for >3 days, during which time the infusion rate of nicorandil was adjusted at the discretion of each physician according to systolic blood pressure (SBP), symptoms or clinical signs. The infusion of nicorandil was stopped when it was judged by each physician that HF had improved. Clinical data were obtained from the medical records of in-and outpatients. Patients were evaluated for severity of HF at the time of hospitalization according to the New York Heart Association (NYHA) classification of HF symptoms. SBP, diastolic blood pressure (DBP), and heart rate at the time of arrival at the emergency department were used as the baseline values. Determination of ischemic heart disease was made on the basis of clinical criteria, including a history of myocardial infarction, angina, or myocardial revascularization, or the results of exercise testing and/or noninvasive imaging. Clinical laboratory tests (including hemoglobin, creatinine, and brain natriuretic peptide (BNP)) were performed using blood samples obtained at arrival at the emergency department. Left ventricular ejection fraction (LVEF) was calculated using either the left ventricular long-axis view on M-mode images or the Simpson method. All participants provided informed consent, and the institutional ethics committee approved the study.
Study Endpoints
The primary endpoint of this study was the occurrence of death from all causes or rehospitalization for HF during the 180-day follow-up analyzed by time to first event. Clinical endpoint information during the 180-day period following the first hospitalization was obtained from medical records when the subjects were inpatients or outpatients during the study period, or obtained via telephone interviews when they were visiting other hospitals.
Statistical Analysis
Data are the mean ± standard deviation, percentages, or medians (interquartile range). The unpaired t-test or Mann-Whitney test was used for unpaired comparisons as appropriate. The Fisher's exact or chi-square test was used to examine differences between categorical variables. The cumulative incidence of death or rehospitalization for HF was estimated according to the Kaplan-Meier method, and the log-rank statistic was used for comparisons. The Cox proportional hazards regression model was used to determine which variables were related significantly to death or rehospitalization for HF during the follow-up. Data are number (%), mean (SD) or median (interquartile ranges). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; BNP, brain natriuretic peptide; IV, intravenous; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
Nicorandil and Prognosis in AHFS
Variable selection in multivariate modeling was based on statistical significance in the univariate analysis (P<0.05). After the data were initially analyzed, we performed a propensity-matched analysis to minimize selection bias. 12 Based on a multivariate logistic regression model, each patient was assigned a propensity score. Covariates in the model included age, sex, comorbidities, vital signs, NYHA class, LVEF, intravenous drugs, and laboratory findings at baseline ( Table 1) . Patients in the Nicorandil and Control groups were matched by 2-digit in a 1:1 ratio, based on the estimated propensity score for treatment with intravenous nicorandil. P<0.05 was considered significant. Statistical analysis was performed using JMP 8.0.1 (SAS Institute Inc, Cary, NC, USA).
Results
A total of 402 consecutive patients with AHFS were registered. The mean age was 79.1±10.4 years, and 189 patients (47.0%) were male ( Table 1) . During the 180-day follow-up, the primary endpoint occurred in 82 patients (20.4%: death from all causes, 42 patients; rehospitalization for HF, 40 patients). Table 1 shows the baseline clinical characteristics of all study participants, those receiving nicorandil (n=78), and those not receiving nicorandil (n=324). The prevalence of hypertension, diabetes mellitus, dyslipidemia and ischemic heart disease was Table 2 . SBP at 72 h in the Nicorandil group was significantly lower than the Control group. DBP at both 24 h and 72 h in the Nicorandil group was significantly lower than the Control group. Proportional pulse pressure was calculated as (SBP−DBP)/SBP. Proportional pulse pressure was significantly higher in patients in the Nicorandil group than in those in the Control group at 24 h and 72 h. There were no significant differences between the 2 groups in heart rate during the 72 h.
Comparison of the Clinical Characteristics, Hemodynamic and Prognosis Between the Nicorandil and Control Groups
During the 180-day follow-up, 7 patients in the Nicorandil group (9.0%) and 75 patients (23.2%) in the Control group died or were rehospitalized for HF; the rate of occurrence was significantly lower in the Nicorandil group (P=0.0053). The rate of death or rehospitalization for HF within 30 days was also significantly lower in the Nicorandil group (2.6% vs. 10.8%, P=0.0238).
Predictors of Death or Rehospitalization for HF
In the univariate Cox hazard analysis of death or rehospitalization for HF during the 180-day follow-up, age (P<0.001), SBP (P<0.001), DBP (P<0.001), heart rate (P<0.01), NYHA class (P<0.001), serum creatinine (P<0.001), hemoglobin (P<0.01), the use of intravenous nicorandil (P<0.01), and the use of intravenous nitroglycerin (P<0.05) were found to be significant factors. The multivariate Cox hazard analysis of these factors revealed that age (hazard ratio (HR)=1.066, 95% confidence interval (CI) 1.036-1.100, P<0.0001), SBP (HR=0.983, 95%CI 0.972-0.994, P=0.0023), NYHA class III or more severe symptoms (HR=6.550, 95%CI 3.161-15.910, P<0.0001), log creatinine (HR=3.866, 95%CI 1.382-10.227, P=0.0106), and use of intravenous nicorandil (HR=0.179, 95%CI 0.073-0.378, P<0.0001) were significant predictive factors for the occurrence of death or rehospitalization for HF ( Table 3) . Figure 1 shows that the event-free survival rates were significantly higher in patients in the Nicorandil group than in those in the Control group (P=0.006). Event-free survival rates were significantly lower in patients with more severe NYHA class symptoms (≥III vs. <III, P=0.0001), patients with lower SBP (<140 vs. ≥140 mmHg, P=0.0086), and patients with higher creatinine level (≥1.3 vs. <1.3 mg/dl, P=0.005). In subanalyses of patients with SBP <140 mmHg (Figure 2A) , NYHA ≥III (Figure 2B) , and serum creatinine ≥1.3 mg/dl (Figure 2C) , the event-free survival rates were significantly higher in patients Tables 1,2 . ISHIHARA S et al.
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in the Nicorandil group than in those in the Control group.
Propensity-Matched Patient Analysis
Estimated propensity scores were used to match 67 patients each from the Nicorandil and Control groups. The baseline clinical characteristics of the patients did not differ between groups ( Table 4) . According to the propensity-matched patient analysis, death or rehospitalization for HF occurred in 7 patients of the Nicorandil group (10.5%) and 22 patients of the Control group (32.8%). During the 180-day follow-up, the incidence of death or rehospitalization for HF was significantly lower in the Nicorandil group than in the Control group (HR=0.276, 95%CI 0.109-0.614, P=0.0012). Figure 3 shows that event-free survival rates were significantly higher in propensity-matched patients of the Nicorandil group than in those of the Control group (P=0.0015).
Discussion
Patients with AHFS often receive intravenous drugs such as loop diuretics, nitrates, and natriuretic peptide analogs and inotropic agents. It has been reported in large-scale registry studies such as ADHERE that the use of inotropic agents increases in-hospital mortality. 13 The effects of vasodilators on the prognosis of patients with AHFS are still being debated. 14, 15 The results of the present study suggest that starting treatment with nicorandil, an intravenous vasodilator, in the urgent phase of AHFS may have decreased the incidence of death or rehospitalization for HF during the 180-day follow-up in 402 consecutive patients with AHFS. Nicorandil differs from classical nitrates, such as nitroglycerin, in its function as a KATP channel activator. 5 Nicorandil exerts a vasodilative effect mainly on the systemic veins, as do conventional nitrates, but it also dilates arteries, including peripheral arteries, by opening KATP channels. By virtue of the well-balanced decrease in both preload and afterload it induces, nicorandil improves the hemodynamics of patients with AHFS. 7, 16 It is recommended that intravenous nicorandil therapy be initiated with a bolus injection to ensure prompt improvement of hemodynamics. Although prompt improvement of hemodynamics should improve the prognosis of patients with AHFS, 4 it has been reported that treatment with the natriuretic peptide analog, nesiritide, may cause deterioration of renal function and thus the prognosis of patients with decompensated HF, possibly via induction of hypotension by bolus administration or continuous infusion of a high dose. 15, 17 In studies in which intravenous bolus injections of nicorandil were given at doses of 0.251 mg/kg 18 and 0.2 mg/kg, 7 nicorandil induced prompt and substantial decreases in pulmonary capillary wedge pressure and systemic vascular resistance, as well as marked increases in the cardiac index without causing an excessive decrease in BP or significant changes in heart rate. In a study of 99 patients with AHFS treated with a bolus injection of nicorandil 0.2 mg/kg followed by continuous infusion at 0.05-0.2 mg · kg -1 · h −1 , Tanaka et al reported that hemodynamics was stable throughout the treatment with nicorandil in all patients except 1 (1%) who exhibited a decrease in BP that did not require discontinuation of the nicorandil infusion. 7 Several reports 6,7,19 have noted that nicorandil significant decreased SBP in patients with high baseline SBP but not in those with low to normal baseline SBP, indicating that nicorandil treatment is safe and efficacious. In this study, all patients in the Nicorandil group received a bolus injection of nicorandil at 0.1-0.2 mg/kg followed by continuous nicorandil infusion at 0.1 mg · kg -1 · h −1 for at least 3 days, during which time the infusion rate of nicorandil was adjusted at the discretion of each physician according to SBP, symptoms or clinical signs. In consequence, nicorandil was administered for a mean of 4.4±1.2 days, at a mean maximum dose of 0.13±0.04 mg · kg -1 · h −1 . Hemodynamics in the Nicorandil group improved promptly Figure 3 . Kaplan-Meier analysis of cumulative event-free rates in propensity-matched patients. Nicorandil and Prognosis in AHFS without causing an excessive decrease in BP. Above all, DBP and proportional pulse pressure at 24 h and 72 h in the Nicorandil group were more improved than those in the Control group, suggesting that nicorandil predominantly dilated peripheral resistant vessels subsequent to increasing cardiac output. 20 Tanaka et al reported that nicorandil can reduce preload in lower infusion rates of <0.1 mg · kg -1 · h −1 , but for further improvement in the afterload and cardiac output via KATP channel opening, a higher infusion rate of 0.2 mg · kg -1 · h −1 would be more appropriate. 7 However, their study was monotherapy of nicorandil, whereas continuous nicorandil infusion at 0.1-0.15 mg · kg -1 · h −1 as in the present study may be able to improve preload and afterload in clinical use (ie, combined therapy with diuretics or other vasodilators). No pronounced hypotension occurred with this nicorandil regimen. All patients could thus receive nicorandil safely. In a subanalysis of the SURVIVE study, the 180-day mortality of patients with severe acutely decompensated HF was 22.5% among those with a ≥30% decrease in BNP level during the first 24 h of treatment, and significantly lower than that in patients with a <30% decrease, 30.3% (HR=0.692, P=0.001). 21 On the other hand, Minami et al 6 and Shirakabe et al 19 reported that during the first 48 h of nicorandil treatment the median plasma BNP level was reduced from 1,639 pg/ml to 623 pg/ml (62% decrease) and from 1,397 pg/ml to 502 pg/ml (65% decrease), respectively. The prompt improvement in hemodynamics by nicorandil might thus have contributed to the improved prognosis of patients with AHFS.
Ischemic heart disease is the most significant disease in patients with AHFS, and patients with it have a worse prognosis than those with nonischemic etiologies. 22, 23 Ischemic heart disease was present in 32.1% of the present patients (it should be noted that patients with acute coronary syndrome were excluded from the study); this prevalence was similar to that in the ATTEND registry study currently underway in Japan. 24 In patients with AHFS, high left ventricular diastolic pressure may induce subendocardial ischemia, which may increase the rate of progression of myocardial damage. Maintaining coronary perfusion may thus play an important role in preventing myocardial injury in patients with AHFS. Nicorandil dilates epicardial conduit arteries through its nitrate-like effect, and dilates coronary resistance vessels by opening KATP channels. 25 Okamura et al have reported that nicorandil is more effective in increasing anterograde coronary blood flow than nitroglycerin alone, without causing the coronary steal phenomenon in patients with ischemic heart disease. 26 A recent report noted that nicorandil improves microvascular dysfunction (as assessed by the index of microcirculatory resistance) after primary percutaneous coronary intervention. 27 Nicorandil also exhibits cardioprotective effects in the ischemic myocardium, similar to those of ischemic preconditioning, via activation of mitochondrial KATP channels. 8, 28 Ishii et al have demonstrated that nicorandil can reduce reperfusion injury and improve clinical outcomes after acute myocardial infarction when administered in adjunctively with coronary intervention. 11 These findings support the usefulness of nicorandil in improving coronary circulation and alleviating myocardial damage in patients with AHFS related to ischemia.
It has also been reported by many studies that intravenous nicorandil administration results in significantly less development of hemodynamic tolerance than nitroglycerin. 29 Because it is important in the treatment of AHFS to decrease cardiac load for a long period of time without causing hemodynamic tolerance, the potential of nicorandil in the treatment of AHFS can thus be considered quite high.
In this study, we found that nicorandil treatment, age, baseline SBP, NYHA class III or more severe symptoms of HF, and baseline creatinine level were independent predictive factors for death or rehospitalization for HF during a 180-day period. These predictive factors for our study population have also been reported to predict the prognosis of patients with AHFS in other studies. 30,31
Study Limitations
This study was retrospective and conducted in a single institution, and there were significant differences in the baseline patient characteristics of the Nicorandil and Control groups. Although statistical techniques were used to decrease the effects of these differences on the results, we cannot rule out the possibility that unspecified factors affected the results of our analysis. There was a difference in the percentage of patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor II antagonists at discharge after propensity analysis. This difference may affect the mid-term prognosis, their use at discharge was not associated with the occurrence of death or rehospitalization for HF during the 180-day follow-up. In addition, because the rate of death or rehospitalization for HF within 30 days was also significantly lower in the Nicorandil group, intravenous nicorandil treatment should improve the prognosis of patients with AHFS. In this study, the percentage of patients receiving intravenous vasodilators in the Control group was 31% and might be low, although the hemodynamic status of the patients at admission was relatively maintained. Several guidelines for the treatment of AHFS have recommend pharmacotherapy with vasodilators in patients without excessively low BP. Prospective randomized studies in a large number of patients should therefore be conducted confirm our findings. However, although our study was retrospective, its findings are significant because it is difficult to prospectively evaluate the benefits of drug treatment in the urgent phase in patients with AHFS.
Conclusions
Our findings suggest that intravenous nicorandil treatment started in the urgent phase of AHFS may improve the prognosis of patients with AHFS.
